The chart below shows how BLFS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BLFS sees a +2.66% change in stock price 10 days leading up to the earnings, and a +7.29% change 10 days following the report. On the earnings day itself, the stock moves by -2.60%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Cell Processing Revenue Growth: BioLife Solutions experienced significant growth in its cell processing platform, achieving a record high revenue of $74 million for the full year 2024, which is a 12% increase compared to 2023.
Gross Margin Improvement: The company reported a GAAP gross margin of 62% in 2024, up from 31% in 2023, indicating improved profitability despite a decrease in total revenue due to divestitures.
Positive EBITDA Turnaround: Adjusted EBITDA for 2024 was positive at $16 million, representing 19% of revenue, a significant turnaround from a negative $5 million in 2023.
Cash Balance Growth: BioLife's cash balance doubled to $109 million by the end of 2024, compared to $45 million in 2023, demonstrating improved financial stability and self-sufficiency.
Projected Revenue Growth: The company anticipates a revenue growth of 16% to 20% for 2025, with projected total revenue between $95.5 million and $99 million, driven primarily by the cell processing platform.
Q4 Revenue Surge: The fourth quarter of 2024 saw a 31% increase in total revenue year-over-year, with cell processing platform revenue increasing by 37%.
Strategic Divestitures Impact: BioLife's strategic divestitures have led to a cleaner balance sheet and a more focused operational approach, enhancing long-term growth potential.
Customer Base Strength: The company has established strong relationships with its top 20 customers, who represent approximately 80% of its biopreservation media revenue, indicating a solid customer base for future growth.
Negative
Revenue Decline Analysis: Total revenue in 2024 was $82 million, a significant decrease from $143 million in 2023 due to divestitures.
Q4 Revenue Decline: EVO and SAW platform revenue for Q4 was $2.4 million, a decrease of $200,000 or 8% from the same period in 2023.
Operating Expenses Increase: GAAP operating expenses for Q4 2024 were $24.8 million, slightly higher than $24.4 million in Q4 2023, indicating rising costs.
Net Loss Comparison: GAAP net loss was $2 million in Q4 2024, compared to $7.2 million in the prior year, although still a loss.
Increased Accounting Expenses: Increased accounting fees related to divestitures and SOX compliance added $900,000 to expenses in Q4 2024, impacting profitability.
R&D Expense Impact: The company anticipates increased R&D expenses in 2025, which could pressure margins despite revenue growth.
Customer Concentration Risk: The reliance on a small number of customers, with top 20 customers representing approximately 80% of BPM revenue, poses a risk to revenue stability.
Market Competition Analysis: The company has not identified any commercial freeze media used in clinical trials, indicating limited competition but also a lack of market diversification.
Earnings call transcript: BioLife Solutions Q4 2024 beats EPS forecast
BLFS.O
-0.24%